← Home / CABALETTA BIO, INC. (CABA)
Stock Analysis
CABALETTA BIO, INC. (CABA)
CABA
CABA · Market data
2.68 -1.47%
Track CABA in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when CABA price is:
52W Range Position
48%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 21:29 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
2.86
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
14
●
Financial Results
HIGH
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
(Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
8-K Filing • SEC EDGAR
MAY
4
●
Financial Results
HIGH
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
PHILADELPHIA, May 4, 2026 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc.
8-K Filing • SEC EDGAR
What's Driving CABA?
📈 Technical recovery is improving
Momentum is Neutral. Watch 2.86 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
Pattern
Triangle Compression
State
Forming
Compression
75%
RSI(14)
41.6
◎
How to read this setup
Pattern note: compression remains elevated around 75%, which means breakout quality matters more than noise inside the pattern.
Price Chart
CABA — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$258.0M
Company size
EV
$165.3M
Debt-adjusted value
P/E
-1.5
Not meaningful
P/B
2.5
Balanced
EV/EBIT
-0.9
Not meaningful
P/FCF
-1.8
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
📈 Net Income
-43.52M
≈ Insufficient
🧮 EPS (Basic)
-0.39
≈ Insufficient
CABALETTA BIO, INC.
Related Opportunities